Have a feature idea you'd love to see implemented?
Let us know!
TARA Protara Therapeutics Inc
Price (delayed)
$2.29
Market cap
$47.24M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.82
Enterprise value
$221,178
Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options. Protara's portfolio includes its lead program, TARA-002, an investigational cell-based
Highlights
The EPS has soared by 54% year-on-year and by 12% since the previous quarter
The debt has decreased by 17% YoY and by 5% from the previous quarter
The company's net income rose by 39% YoY but it fell by 3.3% QoQ
The equity has declined by 11% since the previous quarter but it rose by 6% year-on-year
Protara Therapeutics's quick ratio has decreased by 41% from the previous quarter and by 14% YoY
Key stats
What are the main financial stats of TARA
Market
Valuations
Earnings
Shares outstanding
20.63M
Market cap
$47.24M
Enterprise value
$221,178
Price to earnings (P/E)
N/A
Price to book (P/B)
0.58
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$42.05M
EBITDA
-$41.69M
Free cash flow
-$35.26M
Per share
Balance sheet
Liquidity
EPS
-$2.82
Free cash flow per share
-$1.58
Book value per share
$3.96
Revenue per share
$0
TBVPS
$4.21
Total assets
$94.09M
Total liabilities
$12.3M
Debt
$4.74M
Equity
$81.79M
Working capital
$76.44M
Debt to equity
0.06
Current ratio
9.85
Quick ratio
9.43
Net debt/EBITDA
1.13
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-49.1%
Return on equity
-56%
Return on invested capital
-161.5%
Return on capital employed
-49.2%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TARA stock price
How has the Protara Therapeutics stock price performed over time
Intraday
-0.87%
1 week
-11.24%
1 month
13.93%
1 year
100.88%
YTD
21.81%
QTD
25.14%
Financial performance
How have Protara Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$45.88M
Net income
-$42.05M
Gross margin
N/A
Net margin
N/A
The company's net income rose by 39% YoY but it fell by 3.3% QoQ
TARA's operating income is up by 36% year-on-year but it is down by 3.7% since the previous quarter
Growth
What is Protara Therapeutics's growth rate over time
Valuation
What is Protara Therapeutics stock price valuation
P/E
N/A
P/B
0.58
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has soared by 54% year-on-year and by 12% since the previous quarter
TARA's P/B is 17% below its 5-year quarterly average of 0.7 but 16% above its last 4 quarters average of 0.5
The equity has declined by 11% since the previous quarter but it rose by 6% year-on-year
Efficiency
How efficient is Protara Therapeutics business performance
TARA's return on invested capital has dropped by 70% year-on-year and by 18% since the previous quarter
The ROA has grown by 28% YoY
TARA's ROE is up by 27% year-on-year
Dividends
What is TARA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TARA.
Financial health
How did Protara Therapeutics financials performed over time
Protara Therapeutics's quick ratio has decreased by 41% from the previous quarter and by 14% YoY
Protara Therapeutics's current ratio has decreased by 40% from the previous quarter and by 14% YoY
The debt is 94% less than the equity
Protara Therapeutics's debt to equity has increased by 20% from the previous quarter but it has decreased by 14% YoY
The debt has decreased by 17% YoY and by 5% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.